<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01021215</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-00730</org_study_id>
    <secondary_id>NCI-2013-00730</secondary_id>
    <secondary_id>2009-0804</secondary_id>
    <secondary_id>2009-0804</secondary_id>
    <secondary_id>N01CN35159</secondary_id>
    <nct_id>NCT01021215</nct_id>
  </id_info>
  <brief_title>Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers</brief_title>
  <official_title>Modulation of Arachidonic Acid Metabolism by Chemopreventive Agents in Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn how zileuton alone or the combination of
      zileuton and celecoxib may affect certain chemicals in the body that may be linked with a
      risk for smoking-related lung disease. These effects will be measured by a urine test
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine whether short-term administration of zileuton, a 5-lipoxygenase (5-LO)
      inhibitor, in current smokers will suppress the formation of urinary leukotriene E4 (LTE4)
      and shunt arachidonic acid into the cyclooxygenase (COX) pathway, resulting in elevated
      urinary prostaglandin E-metabolite (PGE-M).

      SECONDARY OBJECTIVES:

      I. To determine whether short-term co-administration of celecoxib, a selective COX-2
      inhibitor, and zileuton suppresses levels of both urinary LTE4 and PGE-M in current smokers.

      II. To evaluate the association between baseline levels of urinary LTE4 and magnitude of the
      arachidonic acid shunt induced by zileuton.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive zileuton orally (PO) twice daily (BID) on days 1-6.

      ARM II: Patients receive zileuton as in Arm I and celecoxib PO BID on days 1-6.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Urinary PGE-M Levels (Pre and Post Treatment)</measure>
    <time_frame>Baseline and Day 6</time_frame>
    <description>Pre and Post treatment differences in urinary PGE-M levels measured in each treatment arm. PGE-M levels reported as median with full range (ng/mg creatinine) for Pre treatment versus Post treatment PGE-M levels among study participants compliant to treatment with evaluable urine samples at both time points (baseline and Day 6 +/- 1 day).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Urinary LTE4 Levels (Pre and Post Treatment)</measure>
    <time_frame>Baseline and day 6</time_frame>
    <description>Pre and Post treatment differences in urinary LTE4 levels measured in each treatment arm compared using paired t-test should the data conform to the normality assumption or one-sample Wilcoxon rank-sum test. LTE4 levels reported as median with full range (pg/mg creatinine) for Pre treatment versus Post treatment LTE4 levels among study participants compliant to treatment with evaluable urine samples at both time points (baseline and Day 6 +/- 1 day).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Cases With a Post-treatment Increase in Urinary PGE-M Levels</measure>
    <time_frame>Baseline to Day 6</time_frame>
    <description>Proportion of cases with a post-treatment increase in urinary PGE-M levels by comparing those treated with Zileuton and Celecoxib combined therapy compared to those treated with Zileuton alone. Pre/postchange in levels (Increase) derived from baseline level to Day 6 +/- 1 day. Differences in baseline levels between 2 treatment arms were examined using the Wilcoxon rank-sum test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Arm I: Zileuton</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zileuton 1200 mg twice orally twice a day on days 1-6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II: Zileuton and Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined Zileuton 1200 mg twice daily plus Celecoxib 200 mg twice daily on days 1-6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zileuton</intervention_name>
    <description>1200 mg twice daily given orally (PO) for 6 days</description>
    <arm_group_label>Arm I: Zileuton</arm_group_label>
    <arm_group_label>Arm II: Zileuton and Celecoxib</arm_group_label>
    <other_name>Zyflo CR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>200 mg twice daily given orally for 6 days</description>
    <arm_group_label>Arm II: Zileuton and Celecoxib</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I: Zileuton</arm_group_label>
    <arm_group_label>Arm II: Zileuton and Celecoxib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female current tobacco smokers with more or equal to 10 pack years of
             self-reported smoking exposure and an average of more or equal to 10 cigarettes/day

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Karnofsky
             70-100%)

          -  Total bilirubin less or equal to 2 * upper limit of normal (ULN)

          -  Direct bilirubin less or equal to 2 * ULN

          -  aspartate aminotransferase (AST)/(SGOT) less or equal to 2 * ULN

          -  alanine aminotransferase (ALT)/(SGPT) less or equal to 2 * ULN

          -  Alkaline phosphatase less or equal to 2 * ULN

          -  If the participant is female, of childbearing potential and not lactating, she has a
             documented negative serum pregnancy test within 14 days prior to randomization

        Exclusion Criteria:

          -  The participant has active cancer (excluding non-melanoma skin cancer)

          -  The participant has a history of curatively treated cancer with surgical therapy
             finished within 6 months prior to the Screening visit; or has had chemotherapy,
             cancer-related immunotherapy, hormonal therapy (other than Hormone replacement therapy
             (HRT) for menopause), or radiation therapy within 12 months of the screening visit

          -  The participant has a chronic inflammatory condition, including but not limited to,
             ulcerative colitis, Crohn's disease, rheumatoid arthritis, psoriasis, gout and
             pancreatitis

          -  The participant has an ongoing or active infection, including but not limited to HIV,
             pneumonia, urinary tract infection

          -  The participant has a history of nonsteroidal anti-inflammatory drugs (NSAIDs) use,
             including aspirin (low-dose aspirin also prohibited) and selective COX-2 inhibitors
             within the previous 4 weeks

          -  The participant has used zileuton or a leukotriene receptor antagonist within the
             previous 4 weeks

          -  The participant has a history of corticosteroid use (excluding topical nasal sprays
             and dermal application) within the last 6 weeks

          -  The participant has an acute or chronic kidney disorder

          -  The participant exhibits clinical evidence of active liver disease or history of
             chronic liver disease

          -  The participant has active cardiac disease, or a history of myocardial infarction,
             angina or coronary artery disease within the past 6 months

          -  The participant has a history of a cerebrovascular accident (CVA) or transient
             ischemic attack (TIA)

          -  The participant has a bleeding history

          -  The participant is taking drugs known to interact with zileuton or celecoxib,
             including theophylline, warfarin, propranolol, fluconazole or lithium

          -  The participant has received any investigational medication within 30 days of the
             screening visit or is scheduled to receive an investigational agent during the study

          -  The participant is pregnant or nursing; women must not be pregnant or lactating

          -  The participant is a female of child-bearing potential (women are considered not of
             childbearing potential if they are at least two years postmenopausal and/or surgically
             sterile) who has not used adequate contraception (abstinence; barrier methods such as
             intrauterine device (IUD), diaphragm with spermicidal gel, condom, or others; and
             hormonal methods such as birth control pills or others) since her last menses prior to
             study entry

          -  The participant is a female of child-bearing potential or male who does not agree to
             use adequate contraception for the duration of study participation; should a woman
             become pregnant or suspect she is pregnant while participating in this study, she
             should inform her study physician immediately

          -  The participant has participated in the study previously and was withdrawn

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant or nursing participants or those who are HIV-positive will be excluded from
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Powel Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas (UT) MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College in New York City, Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center - Consortium Lead Organzation</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas (UT) MD Anderson Cancer Center Official Website</description>
  </link>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2009</study_first_submitted>
  <study_first_submitted_qc>November 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2009</study_first_posted>
  <results_first_submitted>December 17, 2014</results_first_submitted>
  <results_first_submitted_qc>April 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 2, 2015</results_first_posted>
  <last_update_submitted>April 1, 2015</last_update_submitted>
  <last_update_submitted_qc>April 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer Prevention</keyword>
  <keyword>Smoking-related lung disease</keyword>
  <keyword>Smoking</keyword>
  <keyword>Celecoxib</keyword>
  <keyword>Celebrex</keyword>
  <keyword>Zileuton</keyword>
  <keyword>Zyflo CR</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Zileuton</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: May 5, 2010 to September 12, 2011. All recruitment done in medical clinics at Weill Cornell Medical College (WCMC), a Participating Organization within the MD Anderson Cancer Center (MDACC) Consortium.</recruitment_details>
      <pre_assignment_details>A total of 84 subjects were enrolled, four withdrew for different reasons before beginning study medication leaving 80 subjects started on the study medication(s).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I: Zileuton</title>
          <description>Zileuton 1200 mg twice orally twice a day on days 1-6.</description>
        </group>
        <group group_id="P2">
          <title>Arm II: Zileuton and Celecoxib</title>
          <description>Combined Zileuton 1200 mg twice daily plus Celecoxib 200 mg twice daily on days 1-6.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Allocated Intervention</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Of the 80 participants treated three (3) were lost to follow up leaving 77 who completed treatment, and of those reflected as a subset are the 70 compliant participants who completed treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I: Zileuton</title>
          <description>Zileuton 1200 mg twice orally twice a day on days 1-6.</description>
        </group>
        <group group_id="B2">
          <title>Arm II: Zileuton and Celecoxib</title>
          <description>Combined Zileuton 1200 mg twice daily plus Celecoxib 200 mg twice daily on days 1-6.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="25" upper_limit="64"/>
                    <measurement group_id="B2" value="43" lower_limit="30" upper_limit="54"/>
                    <measurement group_id="B3" value="43" lower_limit="25" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking (Packs per Year)</title>
          <description>Number of cigarette packs smoked annually; Measure includes the 70 compliant participants only.</description>
          <units>cigarette packs</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.5" lower_limit="10" upper_limit="68"/>
                    <measurement group_id="B2" value="19.5" lower_limit="10" upper_limit="40"/>
                    <measurement group_id="B3" value="19.5" lower_limit="10" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline PGE-M (ng/mg Cr)</title>
          <description>Prostaglandin E metabolite (PGE-M) levels via creatinine (Cr) in the urine measured by a chemical assay. Baseline measure includes the 70 compliant study participants only.</description>
          <units>ng/mg Cr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.8" lower_limit="1.4" upper_limit="50.4"/>
                    <measurement group_id="B2" value="10.2" lower_limit="2.3" upper_limit="35.1"/>
                    <measurement group_id="B3" value="12.6" lower_limit="1.4" upper_limit="50.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline LTE4 (pg/mg CR)</title>
          <description>Leukotriene E4 (LTE4) levels via creatinine (Cr) in the urine measured by a chemical assay. Baseline measure includes the 70 compliant study participants only.</description>
          <units>pg/mg CR</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107" lower_limit="4" upper_limit="268"/>
                    <measurement group_id="B2" value="86.5" lower_limit="37" upper_limit="250"/>
                    <measurement group_id="B3" value="102.5" lower_limit="4" upper_limit="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Male/Female: Compliant Participants</title>
          <description>Measure includes the 70 compliant study participants only.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race, Compliant Participants</title>
          <description>Baseline measure includes the 70 compliant study participants only.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Continuous, Compliant Participants</title>
          <description>Baseline measure includes the 70 compliant study participants only.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.8" spread="9.6"/>
                    <measurement group_id="B2" value="43.1" spread="7.6"/>
                    <measurement group_id="B3" value="43.6" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Urinary PGE-M Levels (Pre and Post Treatment)</title>
        <description>Pre and Post treatment differences in urinary PGE-M levels measured in each treatment arm. PGE-M levels reported as median with full range (ng/mg creatinine) for Pre treatment versus Post treatment PGE-M levels among study participants compliant to treatment with evaluable urine samples at both time points (baseline and Day 6 +/- 1 day).</description>
        <time_frame>Baseline and Day 6</time_frame>
        <population>Seventy-seven subjects completed the entire study with seven of those excluded from analysis as non-compliant (study medications were undetectable). Urine of two participants contained interfering substances thus were excluded from PGE-M related analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I: Zileuton</title>
            <description>Zileuton 1200 mg twice orally twice a day on days 1-6.</description>
          </group>
          <group group_id="O2">
            <title>Arm II: Zileuton and Celecoxib</title>
            <description>Combined Zileuton 1200 mg twice daily plus Celecoxib 200 mg twice daily on days 1-6.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Urinary PGE-M Levels (Pre and Post Treatment)</title>
          <description>Pre and Post treatment differences in urinary PGE-M levels measured in each treatment arm. PGE-M levels reported as median with full range (ng/mg creatinine) for Pre treatment versus Post treatment PGE-M levels among study participants compliant to treatment with evaluable urine samples at both time points (baseline and Day 6 +/- 1 day).</description>
          <population>Seventy-seven subjects completed the entire study with seven of those excluded from analysis as non-compliant (study medications were undetectable). Urine of two participants contained interfering substances thus were excluded from PGE-M related analysis.</population>
          <units>ng/mg creatinine</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre PGE-M Levels</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="1.4" upper_limit="50.4"/>
                    <measurement group_id="O2" value="13.4" lower_limit="2.3" upper_limit="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post PGE-M Levels</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="2.0" upper_limit="34.6"/>
                    <measurement group_id="O2" value="3.9" lower_limit="1.2" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Urinary LTE4 Levels (Pre and Post Treatment)</title>
        <description>Pre and Post treatment differences in urinary LTE4 levels measured in each treatment arm compared using paired t-test should the data conform to the normality assumption or one-sample Wilcoxon rank-sum test. LTE4 levels reported as median with full range (pg/mg creatinine) for Pre treatment versus Post treatment LTE4 levels among study participants compliant to treatment with evaluable urine samples at both time points (baseline and Day 6 +/- 1 day).</description>
        <time_frame>Baseline and day 6</time_frame>
        <population>Seventy-seven subjects completed the entire study, three withdrew for personal reasons. Seven of those participants were excluded from analysis as non-compliant (study medications were undetectable).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I: Zileuton</title>
            <description>Zileuton 1200 mg twice orally twice a day on days 1-6.</description>
          </group>
          <group group_id="O2">
            <title>Arm II: Zileuton and Celecoxib</title>
            <description>Combined Zileuton 1200 mg twice daily plus Celecoxib 200 mg twice daily on days 1-6.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Urinary LTE4 Levels (Pre and Post Treatment)</title>
          <description>Pre and Post treatment differences in urinary LTE4 levels measured in each treatment arm compared using paired t-test should the data conform to the normality assumption or one-sample Wilcoxon rank-sum test. LTE4 levels reported as median with full range (pg/mg creatinine) for Pre treatment versus Post treatment LTE4 levels among study participants compliant to treatment with evaluable urine samples at both time points (baseline and Day 6 +/- 1 day).</description>
          <population>Seventy-seven subjects completed the entire study, three withdrew for personal reasons. Seven of those participants were excluded from analysis as non-compliant (study medications were undetectable).</population>
          <units>pg/mg creatinine</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre LTE4 levels</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" lower_limit="4" upper_limit="268"/>
                    <measurement group_id="O2" value="86" lower_limit="37" upper_limit="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post LTE4 levels</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="4" upper_limit="292"/>
                    <measurement group_id="O2" value="30" lower_limit="10" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Cases With a Post-treatment Increase in Urinary PGE-M Levels</title>
        <description>Proportion of cases with a post-treatment increase in urinary PGE-M levels by comparing those treated with Zileuton and Celecoxib combined therapy compared to those treated with Zileuton alone. Pre/postchange in levels (Increase) derived from baseline level to Day 6 +/- 1 day. Differences in baseline levels between 2 treatment arms were examined using the Wilcoxon rank-sum test.</description>
        <time_frame>Baseline to Day 6</time_frame>
        <population>Analysis includes only number of participants in each treatment arm with post-treatment increase in urinary PGE-M levels as measured from baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I: Zileuton</title>
            <description>Zileuton 1200 mg twice orally twice a day on days 1-6.</description>
          </group>
          <group group_id="O2">
            <title>Arm II: Zileuton and Celecoxib</title>
            <description>Combined Zileuton 1200 mg twice daily plus Celecoxib 200 mg twice daily on days 1-6.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Cases With a Post-treatment Increase in Urinary PGE-M Levels</title>
          <description>Proportion of cases with a post-treatment increase in urinary PGE-M levels by comparing those treated with Zileuton and Celecoxib combined therapy compared to those treated with Zileuton alone. Pre/postchange in levels (Increase) derived from baseline level to Day 6 +/- 1 day. Differences in baseline levels between 2 treatment arms were examined using the Wilcoxon rank-sum test.</description>
          <population>Analysis includes only number of participants in each treatment arm with post-treatment increase in urinary PGE-M levels as measured from baseline.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".37"/>
                    <measurement group_id="O2" value=".06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events that occur after the informed consent signed (including run-in) until subject off study. Study period was from May 2010 to September 2011.</time_frame>
      <desc>Common Toxicity reporting for the study began with Common Toxicity Criteria for Adverse Effects (CTCAE) version 3.0 and completed with CTCAE version 4.0. Reporting has been combined in the provided tables.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I: Zileuton</title>
          <description>Zileuton 1200 mg twice orally twice a day on days 1-6.</description>
        </group>
        <group group_id="E2">
          <title>Arm II: Zileuton and Celecoxib</title>
          <description>Combined Zileuton 1200 mg twice daily plus Celecoxib 200 mg twice daily on days 1-6.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>EYE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>WATERING EYES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE (3.0)">ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>GERD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST WALL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>RESTLESSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGIC RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>POSTNASAL DRIP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>SORE THROAT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Powel H. Brown, MD Anderson Phase I/II Prevention Consortium</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer</organization>
      <phone>(713) 745-3672</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

